{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"12.2","value":"6.0"},{"groupId":"OG001","lowerLimit":"14.1","upperLimit":"35.5","value":"20.2"},{"comment":"NA=Median OS and upper and lower limits not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA=OS upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG003","lowerLimit":"4.9","upperLimit":"NA","value":"37.1"},{"groupId":"OG004","lowerLimit":"0.4","upperLimit":"28.6","value":"23.8"},{"comment":"NA=Median OS and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.","groupId":"OG005","lowerLimit":"14.7","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"3.6","upperLimit":"7.8","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"41"}],"units":"Participants"}],"description":"OS was defined as the time from first dose of study treatment to death due to any cause. OS was calculated from product-limit (Kaplan-Meier) method for censored data. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 1: Myelodysplastic Syndrome (MDS)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG001","title":"Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG002","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG003","title":"Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)"},{"description":"Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"OG004","title":"Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Cohort 4C: R/R Follicular Lymphoma (FL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"OG006","title":"Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)"}],"paramType":"MEDIAN","populationDescription":"All participants with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}